Ja Min Byun, MD, PhD, discusses response consistency and the future of mezigdomide plus elranatamab in multiple myeloma.
Ja Min Byun, MD, PhD
Advertisement
Articles by Ja Min Byun, MD, PhD
Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
2
FDA Grants Final Approval to Lutetium Lu 177 Dotatate Biosimilar for SSTR+ GEP-NETs
3
FDA Approves Generic Lanreotide Injection for GEP-NETs
4
FDA Flashback: Breast Cancer Decisions and News From August 2026
5